SPONSORED:

House Progressive circulates letter seeking changes to Pelosi drug pricing bill

House Progressive circulates letter seeking changes to Pelosi drug pricing bill
© Aaron Schwartz

A progressive leader among House Democrats on lowering drug prices is circulating a letter calling for “necessary improvements” to Speaker Nancy PelosiNancy PelosiHouse Democrats pass sweeping .9T COVID-19 relief bill with minimum wage hike Budget Committee chair pledges to raise minimum wage: 'Hold me to it' Capitol review to recommend adding more fencing, 1,000 officers: report MORE’s (D-Calif.) signature legislation on the topic. 

The letter from Rep. Lloyd DoggettLloyd Alton DoggettHouse panel advances portion of relief package that includes ,400 checks Democrats urge repeal of business loss tax breaks in relief package Pediatrician killed in hostage situation at Texas medical center MORE (D-Texas), obtained by The Hill, outlines changes that he says need to be made to the legislation Pelosi unveiled earlier this month, which is one of House Democrats’ top legislative priorities.

There has been tension for months as progressives have pushed Pelosi to go further in lowering drug prices in the bill. 

ADVERTISEMENT

Doggett did not explicitly threaten to vote against the legislation if changes are not made, and a spokesperson said he is focused on making improvements and that it is too early to say how he would vote. 

Doggett’s position is key given that it could influence many other progressive House Democrats. Doggett is the sponsor of an alternative bill to lower drug prices that has been endorsed by the Congressional Progressive Caucus. 

“After reviewing her plan, I find much to merit support but some significant limitations that require improvement,” Doggett wrote in a “Dear Colleague” letter to the 129 House Democrats who have co-sponsored his alternative drug pricing bill.

Pelosi’s bill, which congressional Republicans have attacked from the right as being “socialist,” would allow the secretary of Health and Human Services (HHS) to negotiate for lower drug prices. 

But a main concern among progressives, including Doggett, is that Pelosi’s bill would require negotiation for a minimum of 25 drugs per year and a maximum of 250 rather than for all drugs. Doggett called 25 drugs a “very small” number in his letter and objected to the fact that drugs are eligible for negotiation only if they do not have any competition from generic drugs. He noted that would exclude the EpiPen, a drug at the center of outrage over its price in recent years. 

Doggett also expressed concern that the bill does not go far enough to address the launch prices of new drugs arriving on the market for the first time. 

Pelosi has expressed some openness to making changes. She told reporters this month that the number of drugs subject to negotiation is an “open point,” though she noted that there are concerns about the capacity of the HHS secretary to negotiate more drugs. Supporters also note the need to prioritize the most expensive drugs for negotiation.

Pelosi is hoping for the support of President TrumpDonald TrumpBiden to hold virtual bilateral meeting with Mexican president More than 300 charged in connection to Capitol riot Trump Jr.: There are 'plenty' of GOP incumbents who should be challenged MORE for her bill given his sharp rhetoric against drug companies, though that is far from assured, especially amid the impeachment inquiry into him. 

“My objective is not to let the perfect get in the way of the good, but to ensure that the good we seek actually reaches those whom we serve,” Doggett wrote. “In short, more work and amendments are needed to make H.R. 3 effective in achieving our shared objective of lowering drug prices for American families.”